Meeting
2020 ASCO Virtual Scientific Program
Veliparib (V) monotherapy after progression on placebo (PL) + carboplatin/paclitaxel (CP) in patients with advanced HER2-negative gBRCA-associated breast cancer: Crossover outcomes and exploratory biomarker analyses in BROCADE3.
Authors
Shannon L Puhalla
University of Pittsburgh Medical Center Cancer Centers, Pittsburgh, PA
Shannon L Puhalla , Veronique Dieras , Banu Arun , Bella Kaufman , Hans Wildiers , Hyo S. Han , Jean-Pierre M. Ayoub , Vered Stearns , Yuan Yuan , Teresa L. Helsten , Bridget Riley-Gillis , Erin Murphy , Madan Gopal Kundu , Meijing Wu , David Maag , Christine Ratajczak , Cyril Ramathal , Michael Friedlander
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Other Breast Cancer Subtypes
Clinical Trial Registration Number
NCT02163694
Citation
J Clin Oncol 38: 2020 (suppl; abstr 1097)
DOI
10.1200/JCO.2020.38.15_suppl.1097
Abstract #
1097
Poster Bd #
182
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Veliparib (V) monotherapy (monoTx) following combination therapy with V + carboplatin/paclitaxel (CP) in patients with gBRCA-associated advanced breast cancer: Exploratory results from BROCADE3.
First Author: Hyo S. Han
Poster
2015 Breast Cancer Symposium
Phase III randomized, placebo-controlled trial of carboplatin (C) and paclitaxel (P) with/without veliparib (ABT-888) in HER2- BRCA-associated locally advanced or metastatic breast cancer (BC).
First Author: Shannon Leigh Huggins-Puhalla
Poster
2015 ASCO Annual Meeting
Phase 3 randomized, placebo-controlled trial of carboplatin (C) and paclitaxel (P) with/without veliparib (ABT-888) in HER2‒BRCA-associated locally advanced or metastatic breast cancer (BC).
First Author: Shannon Puhalla
Poster
2015 ASCO Annual Meeting
Smoking status to predict sensitivity to PARP inhibitor, veliparib, in patients with advanced NSCLC.
First Author: Suresh S. Ramalingam